12results about How to "Reduce infarct size" patented technology

The invention discloses application of an AXL inhibitor in preparation of a medicine for treating heart failure, and relates to the field of pharmacy. The invention provides application of an AXL inhibitor in a medicine for treating heart failure. The AXL inhibitor can remarkably inhibit abnormal activation of fibroblasts and can remarkably improve the heart function of a mouse with heart failure.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention relates to application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of medicines. In order to solve the problem that a medicine capable of promoting myocardial cell proliferation and inhibiting myocardial cell apoptosis is lacked in the treatment process of the ischemic heart disease, the invention provides application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating the ischemic heart disease. According to the application disclosed by the invention, the expression level of the piRNA-AB352916 in myocardial regeneration model tissues after cardiac apex resection is obviously increased, and animal experiments prove that the myocardial specific overexpression piRNA-AB352916 not only can promote myocardial cell proliferation, but also can inhibit myocardial cell apoptosis, so that the myocardial infarction area is reduced, and the cardiac function of an infarction mouse is improved. The invention proves that the piRNA-AB352916 and the analogue thereof have prevention and treatment values on the ischemic heart disease.

The present invention relates to the technical field of biomaterial preparation, and in particular to an adhesive hydrogel with anti-inflammatory, antioxidant and pro-angiogenic capabilities and its application. The adhesive hydrogel of the present invention comprises an anti-adhesion layer, an adhesion layer and an inner layer arranged in sequence; the anti-adhesion layer and the adhesion layer are respectively formed by cross-linking ACG solutions of different pH values; the inner layer uses methacrylate whey protein as a base material and is loaded with EGCG@DEX‑PBAP. The adhesive hydrogel can be used for the repair of skin damage, muscle damage, nerve damage, and myocardial damage tissue.

The application discloses a multifunctional injectable hydrogel and a preparation method and application thereof, and relates to the technical field of multifunctional hydrogel preparation and application. In the preparation, CMC-AGE and OD-SH are prepared respectively, and DSPE-se-se-PEG@AC NPs nanoparticles are prepared, then the multifunctional injectable hydrogel is prepared by forming a hydrogel through CMC-AGE and OD-SH and adding DSPE-se-se-PEG@AC NPs nanoparticles and / or beta nerve growth factor. The application also includes the multifunctional injectable hydrogel prepared by the above method and the application thereof. The application constructs an in-situ hydrogel delivery platform with good biocompatibility, is used for co-delivery of DSPE-se-se-PEG@AC NPs and NGF, is used in ischemic stroke treatment, and reshapes the pathological microenvironment of a cerebral infarction area, so that cerebral ischemic injury is reduced.

The invention relates to the technical field of medicines, in particular to a medical application of MFAP2 (Microfibril Associated Protein 2). It is found through a large number of experiments that the expression quantity of MFAP2 in heart tissue is reduced along with the increase of time points after newborn rats are born. A myocardial infarction model is established by adopting an anterior descending branch ligation method, an MFAP2 mouse in-vivo overexpression model is established by adopting a caudal vein AAV virus injection method, and it is found that reduction of the cardiac contraction function after myocardial infarction is relieved through mouse in-vivo overexpression of MFAP2. Meanwhile, the fibroblast overexpressing the MFAP2 promotes the proliferation of myocardial cells. The result shows that the MFAP2 protein reduces the cardiac infarction area and improves the cardiac systolic function of patients suffering from myocardial infarction and heart failure by stimulating myocardial cell proliferation and promoting heart regeneration and repair, and can be used as an effective factor for promoting heart repair of patients suffering from cardiovascular diseases.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The invention belongs to the technical field of new application of medicines, and provides application of ginseng epoxy alkynol in preparation of medicines for treating myocardial infarction. The ginseng epoxy alkynol can protect the process of lesion and myocardial infarction caused by left anterior descending branch ligation of the heart to a certain extent, reduce the degree of myocardial fibrosis, reduce the infarction area, relieve ventricular wall tumors, effectively reduce the degree of myocardial infarction and relieve myocardial ischemia after myocardial infarction. The compound has a wide application prospect in treatment of myocardial infarction, especially acute myocardial infarction.

The invention discloses a 2-DG patch, a preparation method and application, and belongs to the technical field of 2-DG patches, the preparation method comprises the following steps: S1, mixing 4% of chitosan and 2% of gelatin according to a weight ratio of 1: 1 to form a patch substrate; s2, adding 1% of 2-DG, fully and uniformly mixing the 2-DG with the patch substrate to form a mixed solution, and centrifuging the mixed solution to remove bubbles and impurities so as to obtain a centrifugate; s3, adding the centrifugate into a culture dish or a pore plate, and drying the culture dish or the pore plate in a drying oven to obtain a dried substance; and S4, soaking the dried substance in a NaOH solution for 30 minutes for deacidification, and washing the dried substance to be neutral by using deionized water to form the 2-DG patch. The 2-DG patch disclosed by the invention can be pasted on the surface of infarcted myocardium, and the slow release of the 2-DG can regulate the polarization of macrophages in a myocardial infarction region, relieve the inflammatory microenvironment in the myocardial infarction region, improve the cardiac function after myocardial infarction, reduce the infarct area and promote heart repair.

The present invention belongs to the field of medicine, and specifically relates to a mitochondrial targeted genistein derivative and its application in the preparation of a drug for the prevention and treatment of myocardial ischemia-reperfusion injury. The general structural formula of the derivative is shown in (I): #imgabs0# Using an animal model of myocardial ischemia-reperfusion injury, experimental results show that the mitochondrial targeted genistein synthesized by the present invention can significantly improve cardiac function, reduce the area of ​​myocardial infarction, and has a significant protective effect on myocardial ischemia-reperfusion injury, and the effect is better than that of genistein.

The invention belongs to the technical field of biology, and particularly relates to a mesenchymal stem cell exosome for overexpressing miR-29 and application of the mesenchymal stem cell exosome. The miR-29 is overexpressed by the mesenchymal stem cells, so that the content of key miRNA in the exosome is remarkably increased, and the function of the exosome in cerebral ischemia treatment is enhanced; the exosome is used as a cell-free treatment mode, so that the risks of cell proliferation, differentiation, immunological rejection and the like possibly caused by MSC transplantation are avoided, and standardization and large-scale preparation are easier; the mesenchymal stem cell exosome of the overexpressed miR-29 can simultaneously realize multiple effects, such as protecting neurons, promoting vascular regeneration, inhibiting inflammatory response, repairing blood-brain barrier and the like, so that cerebral arterial thrombosis can be more comprehensively treated; according to the scheme, through miRNA function enhancement, a stronger treatment effect is provided, and the problems of insufficient function, low miRNA content and weak targeting in existing mesenchymal stem cell exosome treatment are solved.